BMI View: There will be broad healthcare policy continuity in the Philippines under President Rodrigo
Duterte. In contrast to his other more controversial positions, Duterte's statements on healthcare are
relatively more nuanced and in line with current policy direc ..."
BMI View: The Philippine pharmaceutical market is relatively small considering its large population and
disease burden. Low government spending on healthcare, which falls below the WHO's global standards,
and low-income levels limit opportunities for innovative drugma ..."
BMI View: The relative distribution of diseases in the Philippines will remain favourable for multinational
drugmakers. Chronic conditions such as cancer, cardiovascular disease and diabetes will drive demand for
healthcare services and medicines. Access to medicines ..."
BMI View: Healthcare access in the Philippines has improved through the expansion of the country's
universal health insurance scheme and the proposed 2016 government budget will aid further expansion.
The country's growing population, increasing disease burden (partic ..."
BMI View: The proposed 2016 government budget will be positive for the Philippines healthcare sector.
The budget proposes a significant increase in funds allocated to the Department of Health which will
enable authorities to finance the expansion of the country's heal ..."
BMI View: Innovative pharmaceutical companies will continue to face a challenging business environment
in the Philippines. Many concerns limiting the sales of patented drugs in the country remain unaddressed,
including the low levels of intellectual property protectio ..."
BMI View: The Philippine government will face growing headwinds in attracting innovative drugmakers to
expand their operations in the country due to the rising domestic use of generic drugs and the logistical
risks preventing companies from using it as a regional dist ..."
BMI View: Our outlook for the Philippines' pharmaceutical sector remains bullish, driven by an increasing
population and high burden of disease profile. Generic medicines will continue to account for an increasing
share of pharmaceutical sales in the Philippines, galv ..."
BMI View: Medicine pricing controls will continue to limit the growth potential of the Philippine
pharmaceutical market. However, over the longer term progressive implementation of universal healthcare
coverage, coupled with the country's relatively strong economic gr ..."
BMI View: According to the Philippine Institute for Development Studies (PIDS) the pharmaceutical
industry is one of the fastest growing industries in the country. Its output, drugs and medicines, account for
46% of the total medical out-of-pocket expenses of Philippi ..."